The European Market Access Lag: 2021–2024
Pharmaceutical Technology
JUNE 9, 2025
Analysis includes innovative medicines with approved indications or indication extensions that were reimbursed since 2021. On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. Patient profiles were counted distinctly.
Let's personalize your content